Yang Shengnan, Liu Peipei, Jiang Yale, Wang Zai, Dai Huaping, Wang Chen
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
National Center for Respiratory Medicine, Beijing, China.
Front Cell Dev Biol. 2021 Mar 9;9:639657. doi: 10.3389/fcell.2021.639657. eCollection 2021.
Idiopathic pulmonary fibrosis (IPF) is an interstitial disease of unknown etiology characterized by progressive pulmonary fibrosis. Pirfenidone and nintedanib are the only drugs that can prolong the time to disease progression, slow down the decline in lung function, and prolong survival. However, they do not offer a cure and are associated with tolerability issues. The pluripotency of mesenchymal stem cells (MSCs) and their ability to regulate immunity, inhibit inflammation, and promote epithelial tissue repair highlight the promise of MSC therapy for treating interstitial lung disease. However, optimal protocols are lacking for multi-parameter selection in MSC therapy. This review summarizes preclinical studies on MSC transplantation for the treatment of interstitial lung disease and clinical studies with known results. An analysis of relevant factors for the optimization of treatment plans is presented, including MSCs with different sources, administration routes and timing, dosages, frequencies, and pretreatments with MSCs. This review proposes an optimized plan for guiding the design of future clinical research to identify therapeutic options for this complex disease.
特发性肺纤维化（IPF）是一种病因不明的间质性疾病，其特征为进行性肺纤维化。吡非尼酮和尼达尼布是仅有的能延长疾病进展时间、减缓肺功能下降并延长生存期的药物。然而，它们无法治愈疾病，且存在耐受性问题。间充质干细胞（MSC）的多能性及其调节免疫、抑制炎症和促进上皮组织修复的能力，凸显了MSC疗法治疗间质性肺病的前景。然而，在MSC治疗中缺乏用于多参数选择的最佳方案。本综述总结了关于MSC移植治疗间质性肺病的临床前研究以及已知结果的临床研究。文中对优化治疗方案的相关因素进行了分析，包括不同来源的MSC、给药途径和时间、剂量、频率以及MSC的预处理。本综述提出了一个优化方案，以指导未来临床研究的设计，从而为这种复杂疾病确定治疗选择。
